The use of siRNA (short interfering RNA) to study the function of individual genes and during the target validation steps in pharmaceutical development has been established as a powerful, flexible, and easily applied approach.

Analysis of immediate and delayed gene expression events during blood cell development.

At the beginning of the millennium, evidence-based medicine - or individualized treatment for disease based on an individual's genetic code - was thought to be years away. However, scientists from Affymetrix, Stanford University, and deCODE are currently working to turn this goal into reality with new pharmacogenomics research on prostate cancer.